{"transactions":[{"id":2364513,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-01T21:08:48.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":97000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Of the shares of common stock reported, 102,357 shares represent unvested restricted stock units."}],"balance_after":104107,"source":{"system":"sec-edgar","filing":"0001628280-22-004495","document":"wf-form4_164616890458685.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828022004495/wf-form4_164616890458685.xml","form_type":"4"}},{"id":2397282,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-14T21:19:39.000Z","date":"2022-02-11","kind":"sale","acquired":false,"shares":928,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.53 to $1.74, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents unvested restricted stock units."}],"balance_after":7107,"source":{"system":"sec-edgar","filing":"0001628280-22-002505","document":"wf-form4_164487355715189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828022002505/wf-form4_164487355715189.xml","form_type":"4"}},{"id":2771707,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-25T20:56:16.000Z","date":"2021-03-24","kind":"grant","acquired":true,"shares":8035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 11, 2022, February 11, 2023 and February 11, 2024 subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents unvested restricted stock units."}],"balance_after":8035,"source":{"system":"sec-edgar","filing":"0001628280-21-005661","document":"wf-form4_161670575865534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828021005661/wf-form4_161670575865534.xml","form_type":"4"}},{"id":2914803,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-06T13:23:31.000Z","date":"2020-12-31","kind":"grant","acquired":true,"shares":121500,"price":6.43,"value":781245.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on December 31, 2021, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":121500,"derivative":{"exercise_price":6.43,"expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":121500},"source":{"system":"sec-edgar","filing":"0001628280-21-000147","document":"wf-form4_160993939587870.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828021000147/wf-form4_160993939587870.xml","form_type":"4"}},{"id":3090625,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-07-02T20:19:30.000Z","date":"2020-07-01","kind":"sale","acquired":false,"shares":1071,"price":18.3,"value":19599.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":65714,"source":{"system":"sec-edgar","filing":"0000899243-20-018278","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320018278/doc4.xml","form_type":"4"}},{"id":3098239,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-26T20:17:31.000Z","date":"2020-06-25","kind":"exercise","acquired":false,"shares":1459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022."}],"balance_after":12277,"derivative":{"exercise_price":4.83,"expiration_date":"2028-07-10","underlying":"Common Stock","underlying_shares":1459},"source":{"system":"sec-edgar","filing":"0000899243-20-017761","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320017761/doc4.xml","form_type":"4"}},{"id":3098238,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-26T20:17:31.000Z","date":"2020-06-25","kind":"sale","acquired":false,"shares":1459,"price":22,"value":32098.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":66785,"source":{"system":"sec-edgar","filing":"0000899243-20-017761","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320017761/doc4.xml","form_type":"4"}},{"id":3098237,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-26T20:17:31.000Z","date":"2020-06-25","kind":"exercise","acquired":true,"shares":1459,"price":4.83,"value":7046.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":68244,"source":{"system":"sec-edgar","filing":"0000899243-20-017761","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320017761/doc4.xml","form_type":"4"}},{"id":3111395,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-12T21:10:56.000Z","date":"2020-06-10","kind":"exercise","acquired":false,"shares":401,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022."}],"balance_after":13736,"derivative":{"exercise_price":4.83,"expiration_date":"2028-07-10","underlying":"Common Stock","underlying_shares":401},"source":{"system":"sec-edgar","filing":"0000899243-20-016382","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320016382/doc4.xml","form_type":"4"}},{"id":3111394,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-12T21:10:56.000Z","date":"2020-06-10","kind":"sale","acquired":false,"shares":401,"price":22,"value":8822.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":66785,"source":{"system":"sec-edgar","filing":"0000899243-20-016382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320016382/doc4.xml","form_type":"4"}},{"id":3111393,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-12T21:10:56.000Z","date":"2020-06-10","kind":"exercise","acquired":true,"shares":401,"price":4.83,"value":1936.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":67186,"source":{"system":"sec-edgar","filing":"0000899243-20-016382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320016382/doc4.xml","form_type":"4"}},{"id":3118074,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-08T20:17:07.000Z","date":"2020-06-05","kind":"exercise","acquired":false,"shares":451,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022."}],"balance_after":14137,"derivative":{"exercise_price":4.83,"expiration_date":"2028-07-10","underlying":"Common Stock","underlying_shares":451},"source":{"system":"sec-edgar","filing":"0000899243-20-015623","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/doc4.xml","form_type":"4"}},{"id":3118073,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-08T20:17:07.000Z","date":"2020-06-04","kind":"exercise","acquired":false,"shares":226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022."}],"balance_after":14588,"derivative":{"exercise_price":4.83,"expiration_date":"2028-07-10","underlying":"Common Stock","underlying_shares":226},"source":{"system":"sec-edgar","filing":"0000899243-20-015623","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/doc4.xml","form_type":"4"}},{"id":3118072,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-08T20:17:07.000Z","date":"2020-06-05","kind":"sale","acquired":false,"shares":451,"price":20.1791,"value":9100.7741,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $20.31, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":66785,"source":{"system":"sec-edgar","filing":"0000899243-20-015623","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/doc4.xml","form_type":"4"}},{"id":3118071,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-08T20:17:07.000Z","date":"2020-06-05","kind":"exercise","acquired":true,"shares":451,"price":4.83,"value":2178.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":67236,"source":{"system":"sec-edgar","filing":"0000899243-20-015623","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/doc4.xml","form_type":"4"}},{"id":3118070,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-08T20:17:07.000Z","date":"2020-06-04","kind":"sale","acquired":false,"shares":226,"price":20.0498,"value":4531.2548,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":66785,"source":{"system":"sec-edgar","filing":"0000899243-20-015623","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/doc4.xml","form_type":"4"}},{"id":3118069,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-08T20:17:07.000Z","date":"2020-06-04","kind":"exercise","acquired":true,"shares":226,"price":4.83,"value":1091.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":67011,"source":{"system":"sec-edgar","filing":"0000899243-20-015623","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/doc4.xml","form_type":"4"}},{"id":3121584,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-04T20:16:09.000Z","date":"2020-06-03","kind":"exercise","acquired":false,"shares":338,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022."}],"balance_after":14814,"derivative":{"exercise_price":4.83,"expiration_date":"2028-07-10","underlying":"Common Stock","underlying_shares":338},"source":{"system":"sec-edgar","filing":"0000899243-20-015245","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/doc4.xml","form_type":"4"}},{"id":3121583,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-04T20:16:09.000Z","date":"2020-06-02","kind":"exercise","acquired":false,"shares":45,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022."}],"balance_after":15152,"derivative":{"exercise_price":4.83,"expiration_date":"2028-07-10","underlying":"Common Stock","underlying_shares":45},"source":{"system":"sec-edgar","filing":"0000899243-20-015245","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/doc4.xml","form_type":"4"}},{"id":3121582,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-04T20:16:09.000Z","date":"2020-06-03","kind":"sale","acquired":false,"shares":338,"price":20.1763,"value":6819.5894,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.41, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":66785,"source":{"system":"sec-edgar","filing":"0000899243-20-015245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/doc4.xml","form_type":"4"}},{"id":3121581,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-04T20:16:09.000Z","date":"2020-06-03","kind":"exercise","acquired":true,"shares":338,"price":4.83,"value":1632.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":67123,"source":{"system":"sec-edgar","filing":"0000899243-20-015245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/doc4.xml","form_type":"4"}},{"id":3121580,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-04T20:16:09.000Z","date":"2020-06-02","kind":"sale","acquired":false,"shares":45,"price":20,"value":900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":66785,"source":{"system":"sec-edgar","filing":"0000899243-20-015245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/doc4.xml","form_type":"4"}},{"id":3121579,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-04T20:16:09.000Z","date":"2020-06-02","kind":"exercise","acquired":true,"shares":45,"price":4.83,"value":217.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":66830,"source":{"system":"sec-edgar","filing":"0000899243-20-015245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/doc4.xml","form_type":"4"}},{"id":3128685,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-01T20:16:30.000Z","date":"2020-05-29","kind":"exercise","acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022."}],"balance_after":15197,"derivative":{"exercise_price":4.83,"expiration_date":"2028-07-10","underlying":"Common Stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0000899243-20-014722","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/doc4.xml","form_type":"4"}},{"id":3128684,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-01T20:16:30.000Z","date":"2020-05-28","kind":"exercise","acquired":false,"shares":600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022."}],"balance_after":15397,"derivative":{"exercise_price":4.83,"expiration_date":"2028-07-10","underlying":"Common Stock","underlying_shares":600},"source":{"system":"sec-edgar","filing":"0000899243-20-014722","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/doc4.xml","form_type":"4"}},{"id":3128683,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-01T20:16:30.000Z","date":"2020-05-29","kind":"sale","acquired":false,"shares":200,"price":20.035,"value":4007.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.07, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":66785,"source":{"system":"sec-edgar","filing":"0000899243-20-014722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/doc4.xml","form_type":"4"}},{"id":3128682,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-01T20:16:30.000Z","date":"2020-05-29","kind":"exercise","acquired":true,"shares":200,"price":4.83,"value":966.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":66985,"source":{"system":"sec-edgar","filing":"0000899243-20-014722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/doc4.xml","form_type":"4"}},{"id":3128681,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-01T20:16:30.000Z","date":"2020-05-28","kind":"sale","acquired":false,"shares":600,"price":20,"value":12000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":66785,"source":{"system":"sec-edgar","filing":"0000899243-20-014722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/doc4.xml","form_type":"4"}},{"id":3128680,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-06-01T20:16:30.000Z","date":"2020-05-28","kind":"exercise","acquired":true,"shares":600,"price":4.83,"value":2898.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":67385,"source":{"system":"sec-edgar","filing":"0000899243-20-014722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/doc4.xml","form_type":"4"}},{"id":3152117,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Stock Option (right to buy)","published_at":"2020-05-12T20:15:47.000Z","date":"2020-05-12","kind":"exercise","acquired":false,"shares":1860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022."}],"balance_after":15997,"derivative":{"exercise_price":4.83,"expiration_date":"2028-07-10","underlying":"Common Stock","underlying_shares":1860},"source":{"system":"sec-edgar","filing":"0000899243-20-012822","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320012822/doc4.xml","form_type":"4"}},{"id":3152116,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-05-12T20:15:47.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":1860,"price":18,"value":33480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":66785,"source":{"system":"sec-edgar","filing":"0000899243-20-012822","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320012822/doc4.xml","form_type":"4"}},{"id":3152115,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-05-12T20:15:47.000Z","date":"2020-05-12","kind":"exercise","acquired":true,"shares":1860,"price":4.83,"value":8983.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."}],"balance_after":68645,"source":{"system":"sec-edgar","filing":"0000899243-20-012822","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320012822/doc4.xml","form_type":"4"}},{"id":3237135,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-03-02T23:42:26.000Z","date":"2020-03-02","kind":"sale","acquired":false,"shares":315,"price":18.1255,"value":5709.5325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.45, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":66785,"source":{"system":"sec-edgar","filing":"0000899243-20-006590","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320006590/doc4.xml","form_type":"4"}},{"id":3237134,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-03-02T23:42:26.000Z","date":"2020-03-02","kind":"sale","acquired":false,"shares":1828,"price":17.2567,"value":31545.2476,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.91 to $17.85, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":67100,"source":{"system":"sec-edgar","filing":"0000899243-20-006590","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320006590/doc4.xml","form_type":"4"}},{"id":3288056,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Common Stock","published_at":"2020-02-05T21:31:44.000Z","date":"2020-02-03","kind":"sale","acquired":false,"shares":2143,"price":17.3317,"value":37141.8331,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.06 to $17.75, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":68928,"source":{"system":"sec-edgar","filing":"0000899243-20-003272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320003272/doc4.xml","form_type":"4"}},{"id":3301110,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development"}}],"security":"Stock Option (right to buy)","published_at":"2020-01-27T21:30:05.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":55440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 23, 2020 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2020, subject to continued service."}],"balance_after":55440,"derivative":{"exercise_price":16.87,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":55440},"source":{"system":"sec-edgar","filing":"0000899243-20-002040","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924320002040/doc4.xml","form_type":"4"}},{"id":3459100,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":129803,"kind":"person","name":"Cadavid Diego","position":1,"cik":"0001778713","reported_name":"Cadavid Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-07-18T21:26:51.000Z","date":"2019-07-18","kind":"grant","acquired":true,"shares":12784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on July 18, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments from July 1, 2019 through June 30, 2023."}],"balance_after":12784,"derivative":{"exercise_price":16,"expiration_date":"2029-07-17","underlying":"Common Stock","underlying_shares":12784},"source":{"system":"sec-edgar","filing":"0001104659-19-040967","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000110465919040967/a4.xml","form_type":"4"}}]}